|
Aug 3
|
Dow futures drop as recession alarm bells jolt Wall Street awake from dreams of a gravity-defying economy
|
|
Aug 3
|
What To Expect in Markets This Week: Earnings From Palantir, AMD, McDonald’s and More
|
|
Aug 2
|
Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025
|
|
Aug 1
|
McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week
|
|
Aug 1
|
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
|
|
Aug 1
|
Stocks to watch next week: BP, Diageo, Disney, Uber and WPP
|
|
Jul 31
|
What Trump's Big Pharma CEO letters mean for drug pricing power
|
|
Jul 31
|
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
|
|
Jul 31
|
AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
|
|
Jul 31
|
Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs
|
|
Jul 31
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
Jul 31
|
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
|
|
Jul 31
|
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
|
|
Jul 31
|
Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
|
|
Jul 31
|
Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health
|
|
Jul 31
|
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
|
|
Jul 31
|
UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating
|
|
Jul 30
|
Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.
|
|
Jul 30
|
Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out for
|
|
Jul 30
|
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
|